MedTrace Logo

Serotonin Receptor Blockers in Ischemic Mitral Regurgitation

NCT05469165 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 214

Last updated 2023-11-15

No results posted yet for this study

Summary

This study is intended to investigate the effect of cyproheptadine (a 5HT2B receptor blocker) on mitral regurgitation severity.

Conditions

  • Ischemic Mitral Regurgitation

Interventions

DRUG

Cyproheptadine 4 Mg Oral Tablet

Cyproheptadine treatment for 3 months

OTHER

Placebo

Placebo administration for 3months

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • Laval University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-20
Primary Completion
2026-09-30
Completion
2027-09-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05469165 on ClinicalTrials.gov